Liver cancer combo therapy trial halted early

NCT ID NCT05199285

First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 27 times

Summary

This study tested whether combining two immunotherapy drugs, nivolumab and ipilimumab, could shrink tumors in people with advanced liver cancer that had already gotten worse after standard first-line treatment. The trial enrolled 15 adults whose cancer had spread or could not be surgically removed. The study was terminated early, so results are limited.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC HEPATOCELLULAR CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Mayo Clinic in Rochester

    Rochester, Minnesota, 55905, United States

  • Rutgers Cancer Institute of New Jersey

    New Brunswick, New Jersey, 08903, United States

  • University of Alabama- Birmingham

    Birmingham, Alabama, 35233, United States

  • University of Miami Miller School of Medicine-Sylvester Cancer Center

    Miami, Florida, 33136, United States

  • Vanderbilt University/Ingram Cancer Center

    Nashville, Tennessee, 37232, United States

Conditions

Explore the condition pages connected to this study.